LT2012006A - 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui - Google Patents
500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymuiInfo
- Publication number
- LT2012006A LT2012006A LT2012006A LT2012006A LT2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A LT 2012006 A LT2012006 A LT 2012006A
- Authority
- LT
- Lithuania
- Prior art keywords
- fulvestrant
- dosage
- treatment
- breast cancer
- advanced breast
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title abstract 2
- 238000009261 endocrine therapy Methods 0.000 abstract 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Šis išradimas susijęs su 500 mg dozės fulvestrantu, skirtu panaudoti gydyme moterų po menopauzės su išplitusiu krūties vėžiu, kuris progresavo arba recidyvavo endokrininės terapijos metu.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2012006A true LT2012006A (lt) | 2013-03-25 |
| LT5953B LT5953B (lt) | 2013-07-25 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2012006A LT5953B (lt) | 2009-07-27 | 2012-01-24 | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20120214778A1 (lt) |
| EP (1) | EP2459199A1 (lt) |
| JP (1) | JP2013500324A (lt) |
| KR (1) | KR20120042843A (lt) |
| AT (1) | AT510868A2 (lt) |
| AU (1) | AU2010277373A1 (lt) |
| BG (1) | BG111123A (lt) |
| BR (1) | BR112012001837A2 (lt) |
| CA (1) | CA2768286A1 (lt) |
| CL (1) | CL2012000226A1 (lt) |
| CZ (1) | CZ201235A3 (lt) |
| DE (1) | DE112010003084T5 (lt) |
| DK (1) | DK201270089A (lt) |
| EA (1) | EA201200190A1 (lt) |
| EC (1) | ECSP12011629A (lt) |
| EE (1) | EE201200003A (lt) |
| ES (1) | ES2393323A1 (lt) |
| FI (1) | FI20125207A7 (lt) |
| GB (2) | GB0912999D0 (lt) |
| HR (1) | HRP20120084A2 (lt) |
| HU (1) | HUP1200203A3 (lt) |
| IL (1) | IL217527A0 (lt) |
| IS (1) | IS8994A (lt) |
| LT (1) | LT5953B (lt) |
| MX (1) | MX2012001282A (lt) |
| NO (1) | NO20120147A1 (lt) |
| PE (1) | PE20121177A1 (lt) |
| PL (1) | PL399129A1 (lt) |
| RO (1) | RO128705A2 (lt) |
| RS (1) | RS20120022A1 (lt) |
| SE (1) | SE1250155A1 (lt) |
| SG (1) | SG177586A1 (lt) |
| SK (1) | SK500052012A3 (lt) |
| TR (1) | TR201200950T1 (lt) |
| WO (1) | WO2011012885A1 (lt) |
| ZA (1) | ZA201201406B (lt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| MA40271A (fr) * | 2014-05-21 | 2017-03-29 | Hoffmann La Roche | Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| WO2018075071A1 (en) * | 2016-10-21 | 2018-04-26 | Wade Hull | Pharmaceutical compositions |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 FI FI20125207A patent/FI20125207A7/fi not_active Application Discontinuation
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| TW201711676A (en) | Ferric citrate dosage forms | |
| TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| IL247093A0 (en) | Progesterone antagonists such as 4124–cdb in the treatment of breast cancer | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| LT2012006A (lt) | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui | |
| MX2012012523A (es) | Lactonas esteroideas anticancerigenas insaturadas en la posicion 7(8). | |
| PT2320900T (pt) | Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes | |
| MX2011009804A (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. | |
| MX343222B (es) | Combinacion de teobrina con un descongestionante y su uso para el tratamiento de la tos. | |
| MX2012005849A (es) | Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d. | |
| MX2015004759A (es) | Fosfestrol para uso en el tratamiento curativo o paliativo de cancer en mamiferos hembras. | |
| IN2015KN00676A (lt) | ||
| DOP2012000118A (es) | Nuevo uso antitumoral de cabazitaxel | |
| JO3550B1 (ar) | مركب لمعالجة سرطان البروستاتا | |
| CO6531492A2 (es) | Nuevo uso antitumoral de cabazitaxel | |
| UA44831U (ru) | Способ лечения женщин, больных гипертонической болезнью в сочетании с сахарным диабетом ii типа | |
| UA66404U (ru) | Способ профилактики и лечения остеопороза у беременных с перинатальным инфицированием | |
| MY174794A (en) | Anticancer composition | |
| UA43082U (ru) | Способ лечения внутримозгового кровоизлияния | |
| TN2010000464A1 (en) | Dronedarone for the prevention of cardioversion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Patent application published |
Effective date: 20130325 |
|
| FG9A | Patent granted |
Effective date: 20130725 |
|
| MM9A | Lapsed patents |
Effective date: 20140726 |